



# Malaysia

## Western Pacific Region



### I. Epidemiological profile

| Population (UN)                            | 2015       | %  |
|--|------------|----|
| Number of active foci                      | -          |    |
| Number of people living within active foci | 1,531,007  | 5  |
| Malaria-free (0 cases)                     | 28,800,000 | 95 |
| Total                                      | 30,331,000 |    |

| Parasites and vectors                       |  |                   |                       |
|---|--|-------------------|-----------------------|
| Plasmodium species:                         | <i>P. falciparum</i> (7%), <i>P. vivax</i> (4%)  |                   |                       |
| Major anopheles species:                    | <i>An. balabacensis</i> , <i>An. donaldi</i> , <i>An. maculatus</i> , <i>An. sundaicus</i> , <i>An. flavirostris</i> |                   |                       |
| Reported confirmed cases (health facility): | 1,875  | Estimated cases:  | 2,000 [1,900 ; 2,300] |
| Confirmed cases at community level:         | -  |                   |                       |
| Reported deaths:                            | 8  | Estimated deaths: | <10                   |

### II. Intervention policies and strategies

| Intervention   | Policies/strategies  | Yes/No        | Adopted |
|----------------|--|---------------|---------|
| ITN            | ITNs/ LLINs distributed free of charge   | Yes           | 1995    |
|                | ITNs/ LLINs distributed to all age groups  | Yes           | 1995    |
| IRS            | IRS is recommended   | -             | -       |
|                | DDT is authorized for IRS  | No            | -       |
| Larval control | Use of larval control recommended  | Yes           | 1901    |
| IPT            | IPT used to prevent malaria during pregnancy                                       | N/A           | -       |
| Diagnosis      | Patients of all ages should receive diagnostic test                                | Yes           | -       |
|                | Malaria diagnosis is free of charge in the public sector                           | Yes           | 1967    |
| Treatment      | ACT is free of charge for all ages in public sector                                | Yes           | 2008    |
|                | The sale of oral artemisinin-based monotherapies (oAMTs)                           | Never allowed | -       |
|                | Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i> | Yes           | 2013    |
|                | Primaquine is used for radical treatment of <i>P. vivax</i>                        | Yes           | 1993    |
|                | G6PD test is a requirement before treatment with primaquine                        | Yes           | 1993    |
|                | Directly observed treatment with primaquine is undertaken                          | Yes           | -       |
|                | System for monitoring adverse reactions to antimalarials exists                    | Yes           | 2003    |
| Surveillance   | ACD for case investigation (reactive)  | Yes           | 1965    |
|                | ACD of febrile cases at community level (pro-active)                               | Yes           | 1965    |
|                | Mass screening is undertaken   | Yes           | 1965    |
|                | Uncomplicated <i>P. falciparum</i> cases routinely admitted                        | Yes           | 2013    |
|                | Uncomplicated <i>P. vivax</i> cases routinely admitted                             | Yes           | 2013    |
|                | Foci and case investigation undertaken   | Yes           | 1995    |
|                | Case reporting from private sector is mandatory                                    | Yes           | 1988    |


| Antimalarial treatment policy                                 | Medicine   | Year adopted         |
|---|------------|----------------------|
| First-line treatment of unconfirmed malaria                   | -          | -                    |
| First-line treatment of <i>P. falciparum</i>                  | AS+MQ      | -                    |
| Treatment failure of <i>P. falciparum</i>                     | QN+T       | -                    |
| Treatment of severe malaria                                   | QN+T       | -                    |
| Treatment of <i>P. vivax</i>                                  | CQ+PQ(14d) | -                    |
| Dosage of Primaquine for radical treatment of <i>P. vivax</i> |            | 0.50 mg/Kg (14 days) |
| Type pf RDT used  |            | -                    |

| Therapeutic efficacy tests (clinical and parasitological failure, %) |           |      |        |      |           |               |                 |
|--|-----------|------|--------|------|-----------|---------------|-----------------|
| Medicine   | Year      | Min  | Median | Max  | Follow-up | No of studies | Species         |
| CQ   | 2012-2014 | 61.9 | 61.9   | 61.9 | 28 days   | 1             | <i>P. vivax</i> |
| CQ+PQ  | 2006-2007 | 4.3  | 4.3    | 4.3  | 28 days   | 1             | <i>P. vivax</i> |


| Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality) |            |     |           |                 |                        |
|---|------------|-----|-----------|-----------------|------------------------|
| Year  | Pyrethroid | DDT | Carbamate | Organophosphate | Species/complex tested |
| 2010-2014   |            |     |           |                 |                        |

### III. Financing

#### Sources of financing




#### Government expenditure by intervention in 2015




### IV. Coverage

#### Coverage of ITN and IRS




#### Cases tested




### V. Impact


#### Cases treated



#### Test positivity



#### Confirmed malaria cases per 1000 and ABER



#### Number of malaria cases

